Acadia Pharmaceuticals announced that Health Canada has accepted its New Drug Submission, or NDS, for trofinetide for the treatment of Rett syndrome, a rare neurodevelopmental disorder. Health Canada has granted
Acadia Pharmaceuticals announced that Health Canada has accepted its New Drug Submission, or NDS, for trofinetide for the treatment of Rett syndrome, a rare neurodevelopmental disorder. Health Canada has granted
בריאות קנדה החליטה להאיץ את תהליך הבדיקה עבור בקשה זו לתרופה.
The company states: “Acadia Pharmaceuticals announced that two oral presentations featuring DAYBUE findings in Rett syndrome will be presented at the American Academy of Neurology 2024 annual meeting, being held
החברה הודיעה כי היא תעביר שתי הרצאות על DAYBUE, התרופה שלהם, בכנס השנתי של האקדמיה האמריקאית לנוירולוגיה לשנת 2024 בדנבר, קולורדו, השבוע. הם ידברו על ממצאיהם במחקר בשם DAFFODIL(TM), שהיה
Analysts have been eager to weigh in on the Healthcare sector with new ratings on SAGE Therapeutics (SAGE – Research Report), Apellis Pharmaceuticals (APLS – Research Report) and ACADIA Pharmaceuticals (ACAD – Research Report).
SAGE Therapeutics (SAGE)
In a report issued on April 4, Brian Abrahams from RBC Capital maintained a Hold rating on SAGE Therapeutics, with a price target of $26.00. The company’s shares closed last Monday at $16.60, close to its 52-week low of $16.00.
According to TipRanks.com, Abrahams is a 5-star analyst with an average return of
SAGE Therapeutics has an analyst consensus of Hold, with a price target consensus of $25.50.
See Insiders’ Hot Stocks on TipRanks >>
Apellis Pharmaceuticals (APLS)
In a report released today, Joseph Stringer from Needham maintained a Buy rating on Apellis Pharmaceuticals, with a price target of $85.00. The company’s shares closed last Monday at $53.81.
According to TipRanks.com, Stringer is a 3-star analyst with an average return of
Currently, the analyst consensus on Apellis Pharmaceuticals is a Strong Buy with an average price target of $83.29, a 48.8% upside from current levels. In a report issued on March 28, Robert W. Baird also reiterated a Buy rating on the stock with a $100.00 price target.
ACADIA Pharmaceuticals (ACAD)
In a report released today, Ami Fadia from Needham maintained a Buy rating on ACADIA Pharmaceuticals, with a price target of $32.00. The company’s shares closed last Monday at $17.80, close to its 52-week low of $17.56.
According to TipRanks.com, Fadia is a 3-star analyst with an average return of
ACADIA Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $30.23, which is a 69.2% upside from current levels. In a report issued on March 25, J.P. Morgan also maintained a Buy rating on the stock with a $25.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SAGE: